# Study to Asses Efficacy of Intralymphatic Immunotherapy

> **NCT01166269** · PHASE2,PHASE3 · COMPLETED · sponsor: **Rigshospitalet, Denmark** · enrollment: 44 (actual)

## Conditions studied

- Allergy

## Interventions

- **BIOLOGICAL:** phleum pratense (grass-allergen)
- **BIOLOGICAL:** phleum pratense (grass allergen)
- **OTHER:** physiological saline

## Key facts

- **NCT ID:** NCT01166269
- **Lead sponsor:** Rigshospitalet, Denmark
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2012-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01166269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01166269, "Study to Asses Efficacy of Intralymphatic Immunotherapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01166269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*